CancerVax Develops Novel Smart mRNA to Harness Pre-Existing Immunity in 99% of World Population

CancerVax Develops Novel Smart mRNA to Harness Pre-Existing Immunity in 99% of World Population Company completes design and in-vitro validation of a single Smart mRNA that disguises cancer as multiple viral infections simultaneously to activate pre-existing T-cell immunity July 14, 2026 21:06 ET | Source: CancerVAX, Inc CancerVAX, Inc Lehi, Utah, July 14, 2026 (GLOBE NEWSWIRE) -- Lehi, Utah, July 14, 2026 – CancerVax, Inc. , the developer of a breakthrough universal cancer treatment platform that “tricks” the body’s immune system into fighting cancer, today announced that it has successfully developed a single Polyepitope Smart mRNA that can disguise cancer cells as multiple viral infections. The CancerVax platform is designed to harness the body’s existing immunity to detect, mark, and kill cancer cells with precision. At the core of the platform is a Smart mRNA that activates selectively in cancer cells. When activated, this Smart mRNA instructs cancer cells to produce proteins associated with viruses that are highly prevalent in the human population. This effectively disguises cancer cells as familiar viral infections and “tricks” the immune system into recognizing and killing them. “Our earlier work focused on individual viral epitopes, such as measles,” explained Dr. George Katibah, Chief Scientific Officer. “With our Polyepitope Smart mRNA design, we have expanded that concept by encoding multiple viral epitopes with broad population immunity, including measles, influenza, CMV and others, into a single mRNA construct. This approach is designed to increase the probability that a patient’s existing T-cell immunity will recognize at least one of these viral signals and direct an immune response against the cancer cell. Our recent in vitro results provide encouraging validation of this strategy and represent an important step toward a broadly applicable cancer immunotherapy...